================================================================================
United States
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended January 31, 1999
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from: ________________ to _______________
Commission file number: 0-5958
------
MERIDIAN MEDICAL TECHNOLOGIES, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 52-0898764
- ------------------------------- -------------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
10240 Old Columbia Road, Columbia, Maryland 21046
- ------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 410-309-6830
------------
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES [X] NO [ ]
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Class Outstanding as of March 17, 1999
- ---------------------------- --------------------------------
Common Stock, $.10 par value 2,994,930 Shares
================================================================================
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
<TABLE>
<CAPTION>
Page No.
--------
<S> <C>
PART I. FINANCIAL INFORMATION
- -----------------------------
ITEM 1. Consolidated Financial Statements (Unaudited except July 31, 1998 balance sheet)
Consolidated Balance Sheets as of
January 31, 1999 and July 31, 1998............................................................... 4
Consolidated Statements of Operations for
the Three and Six Months Ended January 31, 1999 and 1998 ........................................ 5
Consolidated Statements of Cash Flows for
the Six Months Ended January 31, 1999 and 1998 .................................................. 6
Notes to Consolidated Financial Statements.......................................................... 7
ITEM 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations............................................................. 8
PART II. OTHER INFORMATION
- --------------------------
ITEM 4. Submission of Matters to a Vote of Security Holders................................................ 11
ITEM 5. Other Information.................................................................................. 11
ITEM 6. Exhibits and Reports on Form 8-K................................................................... 11
SIGNATURES.......................................................................................................... 12
</TABLE>
2
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MMT's business plan is to operate as a medical device company focusing on Home
Healthcare and Emergency Medical Technologies. The Company has three areas of
business. The Drug Delivery Systems business capitalizes on injectable drug
delivery devices with an emphasis on commercial auto-injectors. This group also
supplies customized drug delivery system designs, pharmaceutical research and
development, and sterile product manufacturing to pharmaceutical and
biotechnology companies. The Government Systems business focuses on the
worldwide market for auto-injectors used by military and civil defense personnel
for self-administration of nerve agent antidotes, morphine and diazepam. The
Cardiopulmonary Systems business focuses on non-invasive cardiac diagnostics and
telemedicine. It is proceeding on schedule with the implementation of the PRIME
ECG(TM) program, an 80-lead cardiac mapping system for rapid and improved
diagnostic accuracy of cardiac ischemia.
Certain statements in this Quarterly Report on Form 10-Q are forward-looking and
are identified by the use of forward-looking words or phrases such as "will be
positioned", "expects", is or are "expected", "anticipates", and "anticipated".
These forward-looking statements are based on the Company's current
expectations. Because forward-looking statements involve risks and
uncertainties, the Company's actual results could differ materially. In addition
to the factors discussed generally herein, among the factors that could cause
results to differ materially from current expectations are: (i) the general
economic and competitive conditions in markets and countries where the Company
and its subsidiaries offer products and services; (ii) changes in capital
availability or costs; (iii) fluctuations in demand for certain of the Company's
products, including changes in government procurement policy; (iv) technological
challenges associated with the development and manufacture of current and
anticipated products; (v) commercial acceptance of auto-injectors and
competitive pressure from traditional and new drug delivery methods; (vi)
delays, costs and uncertainties associated with government approvals required to
market new drugs and medical devices; (vii) costs of the Company's EpiPen
voluntary recall and/or EpiEZPen voluntary product exchange associated with
differences from management's estimate of the number of returned units, total
costs or adverse impact on future sales; (viii) success and timing of cost
reduction programs; (ix) adequacy of product liability insurance; (x) factors
related to PRIME ECG including successful product completion, degree of market
acceptance and ability to obtain strategic alliances; (xi) changes in the
Medicare and private medical insurance reimbursement and payment policies
applicable to existing products and products under development; (xii) ability of
competitors to design around the Company's patent protection; and (xiii) factors
relating to Year 2000 issues.
3
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
PART I. FINANCIAL INFORMATION
- -----------------------------
ITEM 1. Financial Statements
MERIDIAN MEDICAL TECHNOLOGIES, INC.
-----------------------------------
CONSOLIDATED BALANCE SHEETS
---------------------------
(In thousands, except share data)
---------------------------------
<TABLE>
<CAPTION>
January 31, July 31,
Assets 1999 1998
------ ----------- --------
<S> <C> <C>
Current assets:
Cash and cash equivalents $ 378 $ 284
Restricted cash 275 271
Receivables, less allowances of $346 and $325, respectively 10,043 6,787
Inventories 9,013 8,612
Deferred income taxes 1,661 1,661
Other current assets 799 681
-------- --------
Total current assets 22,169 18,296
-------- --------
Property, plant and equipment 20,317 19,914
Less - Accumulated depreciation 4,619 3,525
-------- --------
Net property, plant and equipment 15,698 16,389
-------- --------
Deferred financing fees 808 836
Capitalized software costs 1,241 545
Excess of cost over net assets acquired, net 7,935 8,325
Other intangible assets, net 2,111 2,456
-------- --------
Total assets $ 49,962 $ 46,847
======== ========
Liabilities and Shareholders' Equity
------------------------------------
Current liabilities:
Accounts payable and other accrued liabilities $ 5,968 $ 7,255
Note payable to bank 8,342 3,988
Customer deposits 629 221
Current portion of long-term debt 1,294 786
-------- --------
Total current liabilities 16,233 12,250
-------- --------
Long-term debt - notes payable, net of discount 17,962 18,453
Long-term debt - other 190 397
Deferred income taxes 1,769 1,769
Other non-current liabilities 737 640
Shareholders' equity:
Common stock (voting and non-voting)
Par value $.10 per share; 18,000,000 shares authorized;
2,994,930 and 2,990,930 shares issued and outstanding 299 299
Additional capital 32,096 32,083
Cumulative translation adjustment 212 (15)
Accumulated deficit (19,218) (18,711)
Unearned stock option compensation (105) (105)
Treasury stock, at cost (213) (213)
-------- --------
Total shareholders' equity 13,071 13,338
-------- --------
Total liabilities and shareholders' equity $ 49,962 $ 46,847
======== ========
</TABLE>
The accompanying notes are an integral part
of these consolidated financial statements.
4
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MERIDIAN MEDICAL TECHNOLOGIES, INC.
-----------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
(In thousands, except per share data)
-------------------------------------
<TABLE>
<CAPTION>
Three Months Ended Six Months Ended
January 31, January 31,
1999 1998 1999 1998
---- ---- ---- ----
<S> <C> <C> <C> <C>
Net sales $ 9,824 $ 10,723 $ 20,674 $ 21,366
Cost of sales 7,422 6,388 14,095 12,896
-------- -------- -------- --------
Gross profit 2,402 4,335 6,579 8,470
Selling, general, and administrative expenses 1,549 1,569 3,379 2,941
Research and development expenses 349 409 597 775
Depreciation and amortization 918 874 1,820 1,765
-------- -------- -------- --------
2,816 2,852 5,796 5,481
-------- -------- -------- --------
Operating (loss) income (414) 1,483 783 2,989
Other (expense) income:
Interest expense (819) (676) (1,667) (1,389)
Other income 366 186 377 194
-------- -------- -------- --------
(453) (490) (1,290) (1,195)
-------- -------- -------- --------
(Loss) income before income taxes (867) 993 (507) 1,794
Provision for income taxes (93) 354 -- 540
-------- -------- -------- --------
Net (loss) income $ (774) $ 639 $ (507) $ 1,254
======== ======== ======== ========
Net (loss) income per share:
Basic $ (.26) $ .22 $ (.17) $ .43
======== ======== ======== ========
Diluted $ (.26) $ .19 $ (.17) $ .38
======== ======== ======== ========
Weighted average shares:
Basic 2,993 2,919 2,992 2,917
Diluted 2,993 3,273 2,992 3,259
</TABLE>
The accompanying notes are an integral part
of these consolidated financial statements.
5
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
MERIDIAN MEDICAL TECHNOLOGIES, INC.
-----------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
(In thousands)
--------------
<TABLE>
<CAPTION>
Six Months Ended
January 31,
1999 1998
---- ----
<S> <C> <C>
OPERATING ACTIVITIES:
Net (loss) income $ (507) $ 1,254
Adjustments to reconcile net (loss) income to net
cash (used for) provided by operating activities:
Depreciation and amortization 1,820 1,765
Amortization of notes payable discount and deferred
financing fees 75 584
Changes in assets and liabilities
Receivables (3,256) 824
Inventories (401) (2,495)
Other current assets (118) 115
Accounts payable and other accrued liabilities (879) 260
Capitalized software costs (696) --
Other 333 (169)
------- -------
Net cash (used for) provided by operating activities (3,629) 2,138
INVESTING ACTIVITIES
Purchase of fixed assets (403) (1,537)
Increase in restricted cash (4) --
------- -------
Net cash used for investing activities (407) (1,537)
FINANCING ACTIVITIES
Net proceeds from line of credit 4,354 576
Net payment on long-term debt -- (750)
Net payment on other long-term debt (207) (232)
Payment of deferred financing fees (30) --
Proceeds from issuance of common stock 13 77
------- -------
Net cash provided by (used for) financing activities 4,130 (329)
------- -------
Net increase in cash 94 272
Cash at beginning of period 284 23
------- -------
Cash at end of period $ 378 $ 295
======= =======
</TABLE>
The accompanying notes are an integral part
of these consolidated financial statements.
6
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. In the opinion of management, the accompanying unaudited consolidated
financial statements contain all adjustments (consisting of normal recurring
accruals) necessary to present fairly the Company's financial position as of
January 31, 1999 and July 31, 1998, the results of its operations for the
three-month and six-month periods ended January 31, 1999 and 1998, and its
cash flows for the six-month periods ended January 31, 1999 and 1998. The
results of operations for the three-month and six-month periods ended
January 31, 1999 are not necessarily indicative of the results that may be
expected for the fiscal year ending July 31, 1999. Certain prior period
amounts have been reclassified to conform to current period presentation.
2. Inventories consisted of the following:
January 31, July 31,
----------- --------
1999 1998
---- ----
Components and subassemblies $ 6,201 $ 6,616
Work in process 3,380 2,262
Finished goods 227 193
------- -------
9,808 9,071
Less: inventory valuation allowance (795) (459)
------- -------
$ 9,013 $ 8,612
======= =======
3. In June 1997, the Financial Accounting Standards Board issued Statement No.
130, Reporting Comprehensive Income, which was adopted by the Company in its
October 1998 financial statements. This Statement establishes standards for
reporting and display of comprehensive income and its components. In
accordance with the Statement, a reconciliation of net income to
comprehensive income is as follows:
Three Months Ended Six Months Ended
January 31, January 31,
1999 1998 1999 1998
---- ---- ---- ----
Net income (loss) $ (774) $ 639 $ (507) $1,254
Foreign exchange translation adjustment 167 (110) 227 74
------ ------ ------ ------
Comprehensive income $ (607) $ 529 $ (280) $1,328
====== ====== ====== ======
4. During the quarter ended January 31, 1999, the Company capitalized $323,000
of software development costs related to a product under development,
bringing the total capitalized to $1,241,000.
7
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The Quarter and Six Months in Review
MMT reported a net loss of $774,000, $(.26) basic and diluted earnings per share
on sales of $9.8 million for the quarter ended January 31, 1999, the second
quarter of fiscal 1999. This compares with net income of $639,000, $0.22 basic
and $.19 diluted earnings per share, on sales of $10.7 million in the same
period of fiscal 1998. On a year-to-date basis, MMT reported a net loss of
$507,000, $(.17) basic and diluted earnings per share on sales of $20.7 million,
compared with net income of $1,254,000, $0.43 basic and $.38 diluted earnings
per share, on sales of $21.4 million in the same period of fiscal 1998. The
adverse results for the current quarter and year-to-date as compared to the
prior year are primarily the result of the EpiPen autoinjector Class 1 product
recall announced on May 8, 1998. The direct cost of the recall was provided for
in previous periods, but the reimbursement of recall costs negatively impacts
current product revenue. As outlined below, the Company's other areas of
business are operating at favorable levels to prior periods.
Revenues of MMT's three areas of business and total gross profit for the
three-month and six-month periods ended January 31, 1999 and 1998 are as
follows:
Three months ended Six months ended
January 31, January 31,
($thousands) 1999 1998 1999 1998
---- ---- ---- ----
Drug Delivery Systems $ 1,460 $ 6,310 $ 7,481 $11,396
Government Systems 7,905 4,120 12,581 9,440
Cardiopulmonary Systems 459 293 612 530
------- ------- ------- -------
Total Revenues 9,824 10,723 20,674 21,366
======= ======= ======= =======
Gross Profit $ 2,401 $ 4,335 $ 6,579 $ 8,470
======= ======= ======= =======
Gross Profit % 24.4% 40.4% 31.8% 39.6%
Drug Delivery Systems business revenue in the fiscal second quarter ended
January 31, 1999 was $1.5 million, $4.8 million lower than in the comparable
prior year period. The 77% decrease in revenue resulted from lower sales of
EpiPens. Reduced sales are heavily influenced by the continued supply of free
EpiPens to replace products returned and to reimburse for cash costs incurred by
the distributor as a result of the May 8, 1998 product recall. The second
quarter has historically been a lower demand quarter for EpiPen. Sales of EpiPen
were unusually high for the quarters ended January 31, 1998 and October 31,
1998. These results each contributed toward the unfavorable EpiPen results for
the quarter ended January 31, 1999 compared to the same quarter of the prior
year. Year-to-date revenues were $7.5 million for the six months ended January
31, 1999, compared to $11.4 million for the same period in the prior year. The
Company has supplied $2.1 million and $5.4 million of free EpiPens during the
three and six months ended January 31, 1999, respectively, and expects to
satisfy substantially all recall obligations during the fiscal third quarter of
1999. Management assesses the adequacy of the reserve on a quarterly basis and
has determined it to be sufficient at January 31, 1999. The growth rate for the
EpiPen product is expected to return to historical rates, following the impact
of the recall.
Year to date activities of the Drug Delivery Systems business included a
continuation of the FDA approval process for generic drugs under the alliance
with Mylan Laboratories with revenues anticipated to start during fiscal 1999.
The ANDA for Acyclovir was received on February 25, 1999, and the Company
expects ANDA's for Diltiazem and Butorphanol during this fiscal year. The
Company continued its program to strengthen its quality processes with the
assistance of consulting firms specializing in biotechnology and medical device
manufacturing. The work of outside consulting firms was substantially completed
as of January 31, 1999.
Government Systems revenues were $7.9 million in the second quarter of fiscal
1999 compared to $4.1 million in the prior year comparable period. The 92%
increase in revenues resulted primarily from higher sales to the USDoD,
reflecting procurements for military readiness. Additionally, civil defense
revenues of $588,000 were
8
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
achieved in the current quarter compared to no revenues in last year's fiscal
second quarter. Year-to-date Government Systems revenues were $12.6 million,
compared to $9.4 million in the prior year. The Company expects to finalize a
contract with a foreign government prior to the end of the fiscal year, which
could produce significant product orders in fiscal 1999 and 2000.
The Company continued contract negotiations with the USDoD for renewal of its
Base Maintenance contract. Similar to the last renewal in 1995, the contract was
extended for six months to allow continuation of procurements while the
three-year renewal contract is being finalized. Progress continued toward
implementation of the MA (multi-chambered auto-injector) project, which will
provide for production of a two-chambered auto-injector. Construction of clean
room facilities for this project is scheduled to start in the fiscal third
quarter. Inquiries and orders continued to build momentum in the civil defense
area, with orders received from various municipalities for fiscal 1999
shipments.
Cardiopulmonary Systems revenues were $459,000 in the current year fiscal second
quarter compared to $293,000 in the prior year. The higher revenues reflected
the introduction of a new ECG monitor called the CardioPocket, which has
received 510(k) approval from the US FDA, and sales have begun in Israel. On a
year-to-date basis, revenues of $612,000 for the first six months of fiscal 1999
compare to $530,000 for fiscal 1998. This increase is primarily the result of
CardioPocket sales in the second quarter.
Progress continues on the PRIME ECG advanced electrocardiac mapping system, and
on January 7, 1999, the Company received CE Mark approval from health
authorities in Europe for marketing the system. The PRIME ECG system has been
studied in more than 3,000 patients in Europe, and U.S. clinical trials are
expected to begin in the coming months. The Company plans to submit an
application to the U.S. FDA in calendar 1999 for approval to market the product
in the United States. The Company is continuing active discussions with
potential marketing partners for the United States, Europe and worldwide.
Gross profits were $2.4 million or 24.4% of revenues during the second quarter
of 1999, compared to $4.3 million or 40.4% for the same period of the prior
year. On a year-to-date basis, gross profit of $6.6 million or 31.8% of revenues
in 1999 compares to $8.5 million or 39.6% in 1998. The reason for the lower
gross profits for the quarter and year-to-date is lower EpiPen sales as
previously explained. While revenues were lower by only $899,000 and $692,000
for the three and six months ended January 31, 1999, respectively, the change in
product mix and the related variable margins negatively impacted the coverage of
fixed costs. The Company expects the gross profit percentage to return to
historical levels, following the impact of the recall.
Operating costs were $2.8 million in the fiscal 1999 second quarter, which is
consistent with the $2.9 million incurred in the second quarter of last year.
For the first six months of the fiscal year, operating costs were $5.8 million
compared to $5.5 million last year. Selling, general and administrative expenses
(SG&A) were $438,000 higher primarily due to consulting expenses associated with
the quality systems review. Partially offsetting the higher SG&A costs were
lower R&D costs. During the first six months of fiscal 1999, the Company
capitalized PRIME software development costs amounting to $696,000, since
technological feasibility was established in December 1997.
Interest expense was $819,000 in the second quarter of fiscal 1999, and $1.7
million year-to-date. This compares to $676,000 in the second quarter of fiscal
1998, and $1.4 million year-to-date. The increased cost for both the quarter and
year-to-date reflects higher long-term debt and increased borrowings on the
working capital line of credit to finance increased levels of receivables and
inventory.
The provision for income taxes in the second quarter of fiscal 1999 was
$(93,000), which offsets the provision recorded in the first quarter. No tax
benefit has been provided on fiscal 1999 year-to-date because of the Company's
net operating loss carryforward position.
The Company implemented steps in January 1999 which are expected to reduce
overhead, product and administrative costs in the future by an estimated $2
million annually.
9
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
Liquidity and Capital Resources
Total cash as of January 31, 1999 was $378,000, an increase of $94,000 from the
prior year ended July 31, 1998. The Company used $3.6 million of cash for
operations in the first six months of fiscal 1999 attributable mostly to the
higher accounts receivable as a result of higher USDoD shipments in the last
month of the quarter. Also included in the use of cash is the building of
inventory to continue to replace returned EpiPens, and to fill USDoD orders,
both currently and during the construction of clean room facilities. Inventories
decreased $1.3 million during the second quarter. Investing activities in the
six months of fiscal 1999 used $407,000 of cash for capital additions. Financing
activities generated $4.1 million, primarily from borrowings on the asset based
working capital line of credit from ING CAPITAL. During the first quarter, the
Company increased its asset based working capital line of credit maximum
availability to $8.5 million from $6.5 million. In connection with the increased
working capital line of credit with ING CAPITAL, capital expenditures in fiscal
1999 have been limited to $3.0 million. Availability under the working lines of
credit was $458,000 at January 31, 1999, which is expected to increase due to
the collection of receivables subsequent to quarter-end. The Company obtained a
waiver of certain debt covenants from ING due to the continued impact of the
EpiPen recall on revenues, and the Company is in compliance with all debt, as
amended, covenants at January 31, 1999. Also due to the impact of the recall,
the Company recognizes that short-term liquidity needs may arise, and is in
current discussions for additional sources of financing, if needed.
Working capital at January 31, 1999 was $7.2 million, up from $6.6 million at
July 31, 1998. The increase was primarily attributable to higher receivables
($3.3 million) and higher inventories ($1.1 million), offset by higher current
liabilities ($4.1 million) mostly from increased borrowings on the credit lines.
At January 31, 1999, accounts receivable were $10.0 million, representing 87
days-sales-outstanding, and inventories were $10.3 million representing a
turn-over rate of 2.7 times per year. The accounts receivable increase was due
primarily to the large volume of USDoD shipments in the last month of the
quarter. The increase in inventory is in preparation for delivery of Government
Systems orders during clean room construction for the MA project at the
Company's St. Louis manufacturing site. Construction of the new clean room
facilities is being funded by the USDoD and will not affect the capital
expenditure limits mentioned above.
Year 2000
The Company is continuing to pursue its program to address the Year 2000 (Y2K)
issue as outlined in its Form 10-K for the year ended July 31, 1998. As of the
date of this filing, all of the Company's systems have a completed plan and are
Y2K compliant, with the exception of Component vendors and Programmable Logic
Controllers (PLC's). Component vendors have submitted formal documentation to
the Company concerning their Y2K readiness and a response/risk assessment is
being performed to evaluate vendor readiness. PLC's used with machinery that
produces product were inventoried and assessed in December 1998. Upgrades to
attain Y2K compliance are now scheduled from January 1999 to September 1999.
The remaining systems with completed plans and which are Y2K compliant are
currently undergoing a validation process, which is expected to be completed by
April 30, 1999.
10
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
PART II - OTHER INFORMATION
ITEM 4. Submission of Matters to a Vote of Security Holders
The Company held its annual meeting of stockholders on January 7, 1999 (the
"Annual Meeting"). A total of 2,666,979 shares of common stock were voted at the
Annual Meeting in person or by proxy. The stockholders voted to reelect Bruce M.
Dresner as a director with 2,646,069 votes cast for the nominee and 20,910
withheld. The stockholders voted to reelect David L. Lougee as a director with
2,641,497 votes cast for the nominee and 25,482 withheld. Finally, the
stockholders voted to ratify the selection by the Board of Directors of Ernst &
Young LLP as independent auditors of the Company for the fiscal year with
2,662,377 votes cast for ratification, 3,010 votes against or withheld, and
1,592 abstentions or broker-nonvotes.
ITEM 5. Other Information
On March 8, 1999, the Company announced that Dennis P. O'Brien was named Vice
President, Finance and Chief Financial Officer, replacing G. Troy Braswell, who
is retiring.
ITEM 6. Exhibits and Reports on Form 8-K:
(a) Exhibits
Exhibit 27 Financial Data Schedule
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the three months ended January 31,
1999.
11
<PAGE>
MERIDIAN MEDICAL TECHNOLOGIES, INC.
FORM 10-Q
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MERIDIAN MEDICAL TECHNOLOGIES, INC.
Registrant
March 17, 1999 By: /S/ James H. Miller
-------------- -------------------------------
Date James H. Miller
President and
Chief Executive Officer
(Principal Executive Officer)
March 17, 1999 By: /S/ Dennis P. O'Brien
-------------- -------------------------------
Date Dennis P. O'Brien
Vice President-Finance
and Chief Financial Officer
(Principal Financial and
Accounting Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
</LEGEND>
<CIK> 0000095676
<NAME> Meridian Medical Technologies, Inc.
<MULTIPLIER> 1,000
<CURRENCY> US Dollars
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUL-31-1999
<PERIOD-START> NOV-1-1998
<PERIOD-END> JAN-31-1999
<EXCHANGE-RATE> 1
<CASH> 653
<SECURITIES> 0
<RECEIVABLES> 10,389
<ALLOWANCES> (346)
<INVENTORY> 9,013
<CURRENT-ASSETS> 22,169
<PP&E> 20,317
<DEPRECIATION> (4,619)
<TOTAL-ASSETS> 49,962
<CURRENT-LIABILITIES> 16,233
<BONDS> 17,962
0
0
<COMMON> 299
<OTHER-SE> 12,772
<TOTAL-LIABILITY-AND-EQUITY> 49,962
<SALES> 9,824
<TOTAL-REVENUES> 9,824
<CGS> (7,422)
<TOTAL-COSTS> (7,422)
<OTHER-EXPENSES> (2,816)
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> (819)
<INCOME-PRETAX> (867)
<INCOME-TAX> 93
<INCOME-CONTINUING> (774)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (774)
<EPS-PRIMARY> (0.26)
<EPS-DILUTED> (0.26)
</TABLE>
